casodex 150 mg
laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 150 mg
casodex 50 mg
laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 50 mg
casodex 50 mg
orifarm as - bikalutamid - tablett, filmdrasjert - 50 mg
casodex 150 mg
orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg
casodex 150 mg
orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg
faslodex
astrazeneca ab - fulvestrant - bryst neoplasms - endokrin terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausal women, kombinert behandling med palbociclib bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.
nasonex 50 mikrog/ dose
n.v. organon - kloosterstraat - mometasonfuroatmonohydrat - nesespray, suspensjon - 50 mikrog/ dose
nasonex 50 mikrog/ dose
farmagon - mometasonfuroat - nesespray, suspensjon - 50 mikrog/ dose
nasonex 50 mikrog/ dose
farmagon - mometasonfuroat - nesespray, suspensjon - 50 mikrog/ dose